Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $1.74M invested in Loncar China BioPharma ETF in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
7% less capital invested
Capital invested by funds: $1.86M → $1.74M (-$124K)
33% less funds holding
Funds holding: 6 → 4 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$802K |
| 2 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$14.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$340K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $1.64M | +$802K | +24,430 | +66% |
|
2
Morgan Stanley
New York
| $59K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $29K | +$4.63K | +141 | +15% |
|
|
BBPWM
4
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $12K | +$14.7K | +449 | New |
|
|
FEM
5
Fulcrum Equity Management
Plano,
Texas
| – | -$340K | -9,126 | Closed |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| – | -$31K | -830 | Closed |
|
CHNA Hedge Fund Activity: Q4 2021 in Review
4 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2021, worth a combined $1.74M — down 6.7% from $1.86M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CHNA and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, adding an estimated $802K. The largest seller was Fulcrum Equity Management, exiting entirely with an estimated $340K sold.
- 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2021, down from 6 in Q3 2021.
- Funds reported $1.74M of Loncar China BioPharma ETF stock for Q4 2021, down 6.7% quarter-over-quarter.
- 1 fund opened new Loncar China BioPharma ETF positions in Q4 2021 and 3 closed out, a net change of -2 holders.
- The largest Loncar China BioPharma ETF buyer in Q4 2021 was Jane Street, an estimated $802K added.
- The largest Loncar China BioPharma ETF seller in Q4 2021 was Fulcrum Equity Management, an estimated $340K sold.
Based on aggregated 13F filings for Q4 2021.